Immunomethylomic profiles of long-term head and neck squamous cell carcinoma survivors on immune checkpoint inhibitors

被引:1
|
作者
Lee, Min Kyung [1 ]
Zhang, Ze [1 ]
Sehgal, Kartik [2 ]
Butler, Rondi [3 ,4 ]
Stolrow, Hannah [1 ]
Ramush, Geat [3 ,4 ]
Shirai, Keisuke [5 ]
Koestler, Devin C. [6 ]
Salas, Lucas A. [1 ]
Wiencke, John K. [7 ]
Haddad, Robert [2 ]
Kelsey, Karl T. [3 ,4 ]
Christensen, Brock C. [1 ,8 ,9 ]
机构
[1] Geisel Sch Med Dartmouth, Dept Epidemiol, Lebanon, NH 03755 USA
[2] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA
[3] Brown Univ, Dept Epidemiol, Sch Publ Hlth, Providence, RI 02903 USA
[4] Brown Univ, Dept Pathol & Lab Med, Sch Med, Providence, RI 02903 USA
[5] Dartmouth Hitchcock Med Ctr, Dept Med, Lebanon, NH 03766 USA
[6] Univ Kansas, Med Ctr, Dept Biostat & Data Sci, Kansas City, KS 66103 USA
[7] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA
[8] Geisel Sch Med Dartmouth, Dept Mol & Syst Biol, Lebanon, NH 03755 USA
[9] Geisel Sch Med Dartmouth, Dept Community & Family Med, Lebanon, NH 03755 USA
基金
美国国家卫生研究院;
关键词
DNA methylation; head and neck squamous cell carcinoma; immune checkpoint inhibitors; immune profiles; immunomethylomics; methylation cytometry; MEMORY T-CELLS; DNA METHYLATION;
D O I
10.1080/17501911.2024.2343274
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Aim: This study addresses the challenge of predicting the response of head and neck squamous cell carcinoma (HNSCC) patients to immunotherapy. Methods: Using DNA methylation cytometry, we analyzed the immune profiles of six HNSCC patients who showed a positive response to immunotherapy over a year without disease progression. Results: There was an initial increase in CD8 T memory cells and natural killer cells during the first four cycles of immunotherapy, which then returned to baseline levels after a year. Baseline CD8 T cell levels were lower in HNSCC immunotherapy responders but became similar to those in healthy subjects after immunotherapy. Conclusion: These findings suggest that monitoring fluctuations in immune profiles could potentially identify biomarkers for immunotherapy response in HNSCC patients.
引用
收藏
页码:799 / 807
页数:9
相关论文
共 50 条
  • [21] Efficacy and safety of immune checkpoint inhibitors in elderly patients (≥70 years) with squamous cell carcinoma of the head and neck
    Saleh, Khalil
    Auperin, Anne
    Martin, Nicolas
    Borcoman, Edith
    Torossian, Nouritza
    Iacob, Mariana
    Ferrand, Francois-Regis
    Khalife, Nadine
    Baste, Neus
    Guigay, Joel
    Le Tourneau, Christophe
    Daste, Amaury
    Saada-Bouzid, Esma
    Even, Caroline
    EUROPEAN JOURNAL OF CANCER, 2021, 157 : 190 - 197
  • [22] Prognostic significance of nutritional indices in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors
    Miyamoto, Noriyuki
    Takenaka, Yukinori
    Sudo, Takato
    Eguchi, Hirotaka
    Tanaka, Hidenori
    Fukusumi, Takahito
    Takemoto, Norihiko
    Suzuki, Motoyuki
    Inohara, Hidenori
    ACTA OTO-LARYNGOLOGICA, 2023, 143 (10) : 925 - 930
  • [23] Inhibition of PNCK inflames tumor microenvironment and sensitizes head and neck squamous cell carcinoma to immune checkpoint inhibitors
    Ding, Qin
    Weng, Youliang
    Li, Ying
    Lin, Wanzun
    Lin, Xiaosan
    Lin, Tingting
    Yang, Hanxuan
    Xu, Wenqian
    Wang, Jianming
    Ying, Hongmei
    Qiu, Sufang
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (10)
  • [24] DNA methylation profiling in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors.
    Starzer, Angelika Martina
    Heller, Gerwin
    Tomasich, Erwin
    Feldmann, Katharina
    Hatziioannou, Teresa
    Traint, Stefan
    Minichsdorfer, Christoph
    Schwarz-Nemec, Ursula
    Nackenhorst, Maja
    Muellauer, Leonhard
    Preusser, Matthias
    Berghoff, Anna Sophie
    Fuereder, Thorsten
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [25] Profiles of immune cell infiltration and their clinical significance in head and neck squamous cell carcinoma
    Jin, Yu
    Qin, Xing
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 82
  • [26] No prime time yet for checkpoint inhibitors in localised head and neck squamous cell carcinoma
    Voortman, Jens
    LANCET ONCOLOGY, 2024, 25 (05): : 533 - 534
  • [27] Obesity and Survival After Immune Checkpoint Inhibition for Head and Neck Squamous Cell Carcinoma
    Mastrolonardo, Eric V.
    Llerena, Pablo
    Lu, Joseph
    Nunes, Kathryn
    Choi, Grace K.
    Amin, Dev
    Bridgham, Kelly M.
    Campbell, Daniel
    Philips, Ramez
    Cognetti, David M.
    Luginbuhl, Adam J.
    Curry, Joseph M.
    JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2024,
  • [28] Gene mutation analysis and immune checkpoint therapy in head and neck squamous cell carcinoma
    Hua Yang
    Yuxue Wei
    Gangli Liu
    Oncology and Translational Medicine, 2022, 8 (01) : 36 - 42
  • [29] Combining Radiation and Immune Checkpoint Blockade in the Treatment of Head and Neck Squamous Cell Carcinoma
    Manukian, Gregor
    Bar-Ad, Voichita
    Lu, Bo
    Argiris, Athanassios
    Johnson, Jennifer M.
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [30] Hyperprogressive disease (HPD) in head and neck squamous cell carcinoma (HNSCC) patients treated with immune checkpoint inhibitors (ICI).
    Alfieri, Salvatore
    Ferrara, Roberto
    Calareso, Giuseppina
    Cavalieri, Stefano
    Platini, Francesca
    Mancinelli, Moela
    Resteghini, Carlo
    Orlandi, Ester
    Iacovelli, Nicola Alessandro
    Ferella, Letizia
    Piazza, Cesare
    Apollonio, Giulia
    Galbiati, Donata
    Bossi, Paolo
    Bergamini, Cristiana
    Locati, Laura Deborah
    Licitra, Lisa F.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)